SGLT2 inhibitors-Sweet success for diabetic kidney disease?

Journal of the American Society of Nephrology

Volumn 28, Issue 1, 2017, Pages 7-10

  De Boer, Ian H ^a,b   Kahn, Steven E ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b Veterans Puget Sound Health Care System   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; CANAGLIFLOZIN; CREATININE; EMPAGLIFLOZIN; GLIMEPIRIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; PIOGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; ANTIDIABETIC AGENT; SODIUM GLUCOSE COTRANSPORTER 2;

ALBUMINURIA; ALL CAUSE MORTALITY; CARDIOVASCULAR RISK; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DISEASE COURSE; EDITORIAL; ESTIMATED GLOMERULAR FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; KIDNEY DISEASE; MACROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; DISEASE EXACERBATION;

BLOOD GLUCOSE; CANAGLIFLOZIN; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; HYPOGLYCEMIC AGENTS; SODIUM-GLUCOSE TRANSPORTER 2; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85019386393     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2016060650     Document Type: Editorial

References (15)

1. Kahn SE, Cooper ME, Del Prato S: Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383: 1068-1083, 2014
2. Lambers-Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V: Canagliflozin slows progression of renal function decline independent of glycemic effects. J Am Soc Nephrol 28: 368-375, 2017
3. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B: Investigators E-RO. Empagliflozin and progression of kidney disease in type 2 diabetes [published online ahead of print June 14, 2016]. N Engl J Med doi:10.1056/NEJMoa1515920
4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 373: 2117-2128, 2015
5. Nathan DM, Cleary PA, Backlund JY, Genuth SM, Lachin JM, Orchard TJ, Raskin P, Zinman B; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.NEngl JMed 353: 2643-2653, 2005
6. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA: 10-year followup of intensive glucose control in type 2 diabetes. N Engl J Med 359: 1577-1589, 2008
7. American Diabetes Association: 7. Approaches toGlycemic Treatment. Diabetes Care 39[Suppl 1]: S52-S59, 2016
8. Kohan DE, Fioretto P, Tang W, List JF: Long-termstudy of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int 85: 962-971, 2014
9. Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G: Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab 101: 157-166, 2016
10. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; TECOS Study Group: Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl JMed 373: 232-242, 2015
11. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326, 2013
12. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F, Investigators E; EXAMINE Investigators: Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327-1335, 2013
13. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB: Investigators LSCobotLT. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes [published online ahead of print June 13, 2016]. N Engl J Med doi:10.1056/NEJMoa1603827
14. Kernan WN, Viscoli CM, Furie KL, Young LH, Inzucchi SE, Gorman M, Guarino PD, Lovejoy AM, Peduzzi PN, Conwit R, Brass LM, Schwartz GG, Adams HP Jr, Berger L, Carolei A, Clark W, Coull B, Ford GA, Kleindorfer D, O'Leary JR, Parsons MW, Ringleb P, Sen S, Spence JD, Tanne D, Wang D, Winder TR, Investigators IT; IRIS Trial Investigators: Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.NEngl J Med 374: 1321-1331, 2016
15. Tuttle KR, BakrisGL, BilousRW, Chiang JL, de Boer IH, Goldstein-Fuchs J, Hirsch IB, Kalantar-Zadeh K, Narva AS, Navaneethan SD, Neumiller JJ, Patel UD, Ratner RE, Whaley-Connell AT, Molitch ME: Diabetic kidney disease: a report froman ADA Consensus Conference. Diabetes Care 37: 2864-2883, 2014